IP Library › Patent Application 11725470
Patent Application
App. No. 11/725,470

Novel method of protecting islet cells from apoptosis during the donor harvesting process

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/725,470
Abstract

The present invention relates to methods for improving the viability and recovery of islets that are separated from a donor organ for subsequent transplantation and more particularly relates to the use of eIF-5A1 siRNAs to enhance the viability of islets.

Claims (15)

1 . A method for inhibiting islet cells from undergoing apoptosis during a donor harvesting process comprising administering eIF-5A1 siRNA to the islet cells of an islet donor prior to islet isolation wherein the eIF-5A1 siRNA inhibits expression of eIF-5A1 in the islet cells and thereby inhibits apoptosis in the islet cells.

2 . The method of claim 1 wherein the eIF-5A 1 siRNA comprises the nucleotide sequence AAAGGAAUGACUUCCAGCUGAdTdT (SEQ ID NO: 2), AAGAUCGUCGAGAUGUCUACUdTdT (SEQ ID NO: 3), AAGGUCCAUCUGGUUGGUAUUdTdT (SEQ ID NO: 4) AAGCUGGACUCCUCCUACACAdTdT (SEQ ID NO: 8), or CGGAAUGACUUCCAGCUGAdTdT (SEQ ID NO: 1).

3 . The method of claim 1 wherein the siRNA is administered via perfusion through the portal vein of the islet cell donor.

4 . The method of claim 1 wherein the siRNA is administered via hydrodynamic perfusion through the portal vein of the islet cell donor.

5 . A method for inhibiting expression of eIF-5A1 in islet cells comprising administering eIF-5A1 siRNA to the islet cells, wherein the eIF-5A1 siRNA inhibits expression of eIF-5A1 in the islet cells.

6 . A method for inhibiting apoptosis in harvested islet cells comprising administering eIF-5A1 siRNA to the islet cells, wherein the eIF-5A1 siRNA inhibits expression of eIF-5A1 in the islet cells and wherein the inhibition of eIF-5A1 expression inhibits apoptosis.

7 . A composition for inhibiting apoptosis in islet cells, comprising eIF-5A1 siRNA, wherein the siRNA inhibits expression of eIF-5A1 and thereby inhibits apoptosis in the islet cells.

8 . The composition of claim 7 wherein the siRNA comprises the nucleotide sequence AAAGGAAUGACUUCCAGCUGAdTdT (SEQ ID NO: 2).

9 . The composition of claim 1 wherein the eIF-5A1 siRNA comprises the nucleotide sequence AAAGGAAUGACUUCCAGCUGAdTdT (SEQ ID NO: 2).

10 . The method of claim 1 wherein the eIF-5A1 siRNA comprises the nucleotide sequence AAGAUCGUCGAGAUGUCUACUdTdT (SEQ ID NO: 3).

11 . The method of claim 1 wherein the eIF-5A1 siRNA comprises the nucleotide sequence AAGGUCCAUCUGGUUGGUAUUdTdT (SEQ ID NO: 4).

12 . The composition of claim 7 wherein the eIF-5A1 siRNA comprises the nucleotide sequence AAGCUGGACUCCUCCUACACAdTdT (SEQ ID NO: 8).

13 . The composition of claim 7 wherein the eIF-5A1 siRNA comprises the nucleotide sequence AAGGUCCAUCUGGUUGGUAUUdTdT (SEQ ID NO: 4).

14 . The composition of claim 7 wherein the eIF-5A1 siRNA comprises the nucleotide sequence CGGAAUGACUUCCAGCUGAdTdT (SEQ ID NO: 1).

15 . The method of claim 1 wherein the eIF-5A1 siRNA targets the following nucleotide sequences of eIF-5A1: 5′-AAAGGAATGACTTCCAGCTGA-3′ (SEQ ID NO: 9); 5′-AAGATCGTCGAGATGTCTACT-3′ (SEQ ID NO: 10); 5′-AAGGTCCATCTGGTTGGTATT-3′ (SEQ ID NO: 11); or 5′-AAGCTGGATCCCTCCTACACA-3′ (SEQ ID NO: 12).

Assignments (3)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Mar 25, 2010
From: YA GLOBAL INVESTMENTS, L.P.
To: SENESCO TECHNOLOGIES, INC.; SENESCO, INC.
Reel/Frame 024128/0676 →
SECURITY AGREEMENT Recorded Feb 5, 2008
From: SENESCO TECHNOLOGIES, INC.; SENESCO, INC.
To: YA GLOBAL INVESTMENTS, L.P.
Reel/Frame 020468/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2007
From: THOMPSON, JOHN E.; DINARELLO, CHARLES A.
To: SENESCO TECHNOLOGIES, INC.
Reel/Frame 019999/0300 →